# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 4069
- Completion tokens: 26808
- Reasoning tokens: 
- Total tokens: 30877
- API requests reported: 
- Elapsed seconds: 256.93
- Final benchmark system: raw; file rank 2/5; original repeat 4; model vendor: DeepSeek

---
Because this is a disease-state comparison (ulcerative colitis versus healthy control), there is no prognostic endpoint or hazard ratio in the input. All effect directions below refer to log2FC in UC mucosa relative to control. All genes listed have very low FDR values, so the differential-expression call itself is statistically strong, but biological interpretation requires separating signal that reflects disease mechanism from signal that may reflect tissue composition, treatment, or generic inflammatory damage.

## 1. Overall biological interpretation

The supplied colonic mucosal transcriptome in active UC is not simply “inflammation up, metabolism down.” It describes a coordinated mucosal injury state with at least four interconnected features:

- A strong epithelial antimicrobial/oxidative defense response, including DUOX2/DUOXA2, SLC6A14, LCN2, S100A8, PI3, REG4, PLA2G2A, and CHI3L1.
- A neutrophilic/NF-κB/IL-17-driven inflammatory amplification program, seen in CXCL1/CXCL2/CXCL3, S100A8/S100P, LCN2, VNN1, MMP3, and IL1RN.
- A broad loss of differentiated colonocyte metabolic, transport, and detoxification programs, including HMGCS2, AQP7/AQP8, SLC38A4, SLC16A1, SLC51A, SLC23A1/SLC23A3, CYP2B6/CYP2B7P, UGT2A3, ABCG2, and MEP1B.
- An adaptive immune/plasma-cell and T-cell regulatory component, reflected by immunoglobulin heavy-chain transcripts, DAPP1, CTLA4, and possibly UBD.
- A tissue remodeling/EMT/fibrosis signal, including MMP3, TIMP1, TNC, PRRX1, PDPN, TGM2, CDH3, and SERPINB5.

The simultaneous upregulation of negative regulators such as IL1RN, SOCS3, IRAK3, and CTLA4 suggests active anti-inflammatory/immune-checkpoint feedback, not uncontrolled one-way activation. The broad downregulation of epithelial metabolic transporters and detoxification enzymes likely reflects either loss of mature colonocytes, epithelial dedifferentiation, or a metabolically compromised epithelium. Overall, the data support the model of UC as a disease of epithelial barrier/antimicrobial failure with excessive innate and adaptive immune amplification and tissue remodeling.

---

## 2. Core biological programs

### Program 1: Epithelial antimicrobial/ROS defense and barrier maintenance
- **Direction:** Predominantly upregulated in UC; one notable downregulated gene: DEFB1.
- **Supporting genes:** SLC6A14, DUOX2, DUOXA2, LCN2, S100A8, S100P, PI3, REG4, PLA2G2A, CHI3L1; DEFB1 (down).
- **Representative pathway:** GO: antimicrobial humoral response / defense response to bacterium; Reactome: antimicrobial peptides.
- **Explanation:** DUOX2/DUOXA2 form an epithelial H2O2-generating system; LCN2 sequesters bacterial siderophores; S100A8/S100A9 are antimicrobial alarmins; PI3/elafin and PLA2G2A contribute to antimicrobial protease/lipid defenses; REG4 is a regenerating epithelial defense gene. The decreased DEFB1 is interesting because it suggests loss of constitutive β-defensin-1 expression, possibly reflecting epithelial damage/dedifferentiation rather than a simple global antimicrobial activation.
- **Strength/limitations:** Strong because the signal is supported by multiple independent gene families. Limitation: several of these genes are also expressed by neutrophils or other immune cells, so the epithelial contribution cannot be proven from bulk tissue alone.

### Program 2: Neutrophilic inflammation and NF-κB/IL-17-driven amplification
- **Direction:** Upregulated in UC.
- **Supporting genes:** CXCL1, CXCL2, CXCL3, S100A8, S100P, LCN2, CHI3L1, VNN1, MMP3, TIMP1, IL1RN, SOCS3, IRAK3.
- **Representative pathway:** KEGG: IL-17 signaling pathway; Hallmark: TNF-alpha signaling via NF-κB; Reactome: neutrophil degranulation.
- **Explanation:** CXCL1/2/3 are neutrophil chemoattractants acting through CXCR2. S100A8/S100P and LCN2 are alarmin/neutrophil-associated proteins that can amplify innate inflammation. CHI3L1 and VNN1 are inflammatory/oxidative-stress-responsive proteins. The presence of IL1RN, SOCS3, and IRAK3 indicates concurrent negative feedback on IL-1, JAK/STAT, and TLR signaling.
- **Strength/limitations:** Strong multi-gene signal and very consistent with active UC. Limitation: this program overlaps with Program 1, and the expression could largely reflect infiltrating neutrophils rather than mucosal epithelial cells.

### Program 3: Loss of mature colonocyte metabolic, transport, and detoxification programs
- **Direction:** Downregulated in UC.
- **Supporting genes:** SLC38A4, SLC23A1, SLC23A3, SLC16A1, SLC51A, SLC19A3, SLC25A34, SLC35G1, AQP7, AQP8, HMGCS2, G6PC, TAT, HSD3B2, CYP2B6, CYP2B7P, UGT2A3, ABCG2, ABCB11, MEP1B, B4GALNT2, GCNT2, ETNK1, ACSF2, NAT8B.
- **Representative pathway:** KEGG: bile secretion; KEGG: PPAR signaling pathway; Reactome: SLC-mediated transmembrane transport; Hallmark: xenobiotic metabolism.
- **Explanation:** These genes represent functions of healthy, differentiated colonocytes: ketogenesis (HMGCS2), water transport (AQP7/AQP8), bile acid/transporter handling (SLC51A, ABCB11), xenobiotic metabolism and efflux (CYP2B6, UGT2A3, ABCG2), nutrient/vitamin transport (SLC23A1/3, SLC19A3, SLC16A1, SLC38A4), and brush-border/mucosal glycosylation (MEP1B, B4GALNT2, GCNT2). Their coordinated downregulation is consistent with crypt loss, epithelial dedifferentiation, or metabolic failure in active UC.
- **Strength/limitations:** Strong as a coordinated transcriptomic pattern. However, because this is bulk mucosal tissue, the downregulation may partly reflect loss of epithelial cell proportion rather than reduced expression within each colonocyte. Some genes, such as ABCB11 and TAT, are not typical colonic epithelial genes and may reflect probe ambiguity or unusual tissue expression; targeted validation is needed.

### Program 4: Adaptive immune activation with B/plasma-cell and T-cell checkpoint components
- **Direction:** Upregulated in UC.
- **Supporting genes:** LOC100290146|IGHV4-31|IGHM|IGHG1|IGH, CTLA4, DAPP1, UBD|GABBR1 (UBD contribution), CD55.
- **Representative pathway:** Reactome: adaptive immune system; KEGG: B cell receptor signaling pathway; KEGG: T cell receptor signaling pathway.
- **Explanation:** Increased immunoglobulin heavy-chain transcripts strongly suggests plasma-cell infiltration and local antibody production. DAPP1 is a B-cell adaptor protein and supports BCR signaling. CTLA4 marks activated/T-regulatory T cells and is a checkpoint/negative-regulatory molecule. UBD/FAT10 is an interferon/NF-κB-inducible ubiquitin-like protein involved in antigen presentation and immune activation.
- **Strength/limitations:** Moderate strength because the number of genes is limited and all could be explained by immune-cell infiltration rather than a tissue-intrinsic program. CTLA4 upregulation should not be read as purely pro-inflammatory; it may represent a regulatory brake.

### Program 5: Tissue remodeling, EMT-like change, and fibrosis/wound repair
- **Direction:** Upregulated in UC.
- **Supporting genes:** MMP3, TIMP1, TNC, PRRX1, PDPN, CDH3, SERPINB5, TGM2, FILIP1L.
- **Representative pathway:** Hallmark: epithelial–mesenchymal transition; Reactome: extracellular matrix organization.
- **Explanation:** MMP3 degrades extracellular matrix and is strongly induced in UC. TIMP1 is its endogenous inhibitor and is also highly upregulated. TNC is an inducible ECM glycoprotein. PRRX1 is a transcription factor associated with EMT and mesenchymal remodeling. PDPN, TGM2, CDH3, and SERPINB5 are consistent with epithelial plasticity, wound healing, or stromal activation. This pattern likely reflects ulceration, matrix degradation, and attempted repair in chronic inflammation.
- **Strength/limitations:** Multiple coherent genes support this program, but bulk-tissue EMT evidence is inherently limited. PRRX1/PDPN may be stromal or lymphatic markers rather than proof that colonocytes are undergoing EMT.

---

## 3. Key genes and interaction modules

### 3.1 DUOX2 + DUOXA2
- **Direction:** Both upregulated (DUOX2 log2FC ~4.67; DUOXA2 ~2.89).
- **Role:** Epithelial NADPH oxidase system generating H2O2; DUOXA2 is required for DUOX2 maturation and membrane expression.
- **Gene-gene relationship:** Direct physical/functional interaction; DUOXA2 acts as a maturation factor for DUOX2.
- **Evidence:** Input dataset; pathway/functional literature; genetic literature linking DUOX2 variants to very early onset IBD. The genetic evidence creates an important caveat: DUOX2 loss can predispose to IBD, so its upregulation in active UC may be compensatory/protective rather than purely harmful.

### 3.2 CXCL1/CXCL2/CXCL3 module
- **Direction:** All upregulated.
- **Role:** CXC chemokines that recruit neutrophils via CXCR2; downstream effectors of NF-κB and IL-17.
- **Gene-gene relationship:** Co-expression and pathway co-membership; not direct physical interaction.
- **Evidence:** Input dataset; pathway/ontology evidence; established immunology. This module supports the neutrophilic inflammation program.

### 3.3 S100A8 + LCN2 module
- **Direction:** Both upregulated.
- **Role:** S100A8/S100A9 (calprotectin) is an alarmin and established fecal IBD biomarker; LCN2/NGAL is an antimicrobial/neutrophil protein and candidate stool biomarker.
- **Gene-gene relationship:** S100A8 directly heterodimerizes with S100A9 (not in this table), but S100A8 and LCN2 are not direct interactors; they are co-expressed/co-secreted in neutrophil and epithelial alarmin responses.
- **Evidence:** Input dataset; disease-association and biomarker literature. Overlap warning: co-upregulation may reflect the same neutrophil infiltrate, not independent biological signals.

### 3.4 MMP3 + TIMP1 + TNC module
- **Direction:** All upregulated.
- **Role:** ECM remodeling and mucosal injury/repair. MMP3 degrades matrix; TIMP1 inhibits MMPs; TNC is an injury-associated ECM glycoprotein.
- **Gene-gene relationship:** TIMP1 is a direct protein inhibitor of MMP3. TNC is better viewed as an ECM/pathway co-member than a confirmed direct physical partner.
- **Evidence:** Input dataset; protein interaction literature; published IBD association of MMP3. This module is central to Program 5.

### 3.5 HMGCS2 + AQP8 + ABCG2 module
- **Direction:** All downregulated.
- **Role:** Markers of mature colonocyte function: HMGCS2 in ketogenesis, AQP8 in water transport, ABCG2 in xenobiotic efflux. Their loss suggests epithelial metabolic/functional dedifferentiation.
- **Gene-gene relationship:** Co-expression and pathway co-membership in differentiated colonocytes; no direct physical interaction proposed.
- **Evidence:** Input dataset; expression/tissue-specific literature. Major caveat: in bulk tissue, downregulation may reflect loss of epithelial cells rather than downregulation per cell.

### 3.6 IGH + CTLA4 + DAPP1 module
- **Direction:** Upregulated. The IGH entry is a multi-gene/ambiguous probe (IGHV4-31|IGHM|IGHG1|IGH).
- **Role:** Plasma-cell immunoglobulin production, B-cell signaling (DAPP1), and T-cell checkpoint/regulatory activity (CTLA4).
- **Gene-gene relationship:** Pathway co-membership in the adaptive immune response; not direct physical interactions. These genes may come from different immune cell populations (plasma cells, B cells, T cells).
- **Evidence:** Input dataset; published immunology of UC. The probe ambiguity and immune-cell composition are limitations.

### 3.7 IL1RN + SOCS3 + IRAK3 module
- **Direction:** All upregulated.
- **Role:** Negative regulators of IL-1 signaling, JAK/STAT signaling, and TLR signaling, respectively. This module indicates active anti-inflammatory feedback during mucosal inflammation.
- **Gene-gene relationship:** Co-expression in a shared negative-feedback regulatory environment; no direct physical interaction proposed.
- **Evidence:** Input dataset; functional literature. This is biologically important because it argues against interpreting every upregulated gene as pro-inflammatory.

### 3.8 SLC6A14
- **Direction:** Upregulated; one of the strongest signals in the list (log2FC ~4.85).
- **Role:** SLC6A14 encodes B0AT1, an amino acid transporter expressed in intestinal epithelium. It may support epithelial amino acid uptake, polyamine metabolism, or microbial defense, but its exact role in UC remains incompletely defined.
- **Gene-gene relationship:** Likely co-expressed with other epithelial stress/defense genes such as DUOX2 and LCN2, but the relationship is indirect/putative, not established direct interaction.
- **Evidence:** Input dataset; disease-association literature. Insufficient evidence for a specific causal mechanism.

### 3.9 PRRX1 + PDPN + TGM2 module
- **Direction:** All upregulated.
- **Role:** Tissue remodeling/EMT/fibrosis: PRRX1 is an EMT-associated transcription factor; PDPN is a lymphatic/mesenchymal marker; TGM2 crosslinks ECM proteins.
- **Gene-gene relationship:** PRRX1 may regulate downstream EMT genes, but the relationship with PDPN/TGM2 in this dataset is best described as regulatory/indirect or co-expression; no direct physical interaction is established.
- **Evidence:** Input dataset; pathway annotation; published fibrosis/EMT literature. This module should be treated carefully because bulk-tissue EMT is difficult to prove.

---

## 4. Validation priorities

### 4.1 DUOX2/DUOXA2 oxidative antimicrobial mechanism
- **Classification:** Mechanistic hypothesis.
- **Why prioritize:** DUOX2/DUOXA2 are among the strongest upregulated signals and define an epithelial-specific oxidative antimicrobial pathway relevant to UC.
- **Dataset evidence:** Strong co-upregulation of DUOX2 and DUOXA2 with very low FDR.
- **External evidence:** Published data show DUOX2 is induced by IFN-γ, TNF, and microbial products; DUOX2 loss-of-function variants are linked to very early onset IBD. This creates a conflict: DUOX2 may be protective in host defense, while excessive activity may cause oxidative tissue injury.
- **Next step:** Use human colonic organoids or epithelial cell lines with DUOX2/DUOXA2 knockdown or pharmacological inhibition; measure H2O2 production, bacterial handling, epithelial permeability, and inflammatory cytokine release.
- **Current conclusion:** Supported hypothesis, not established causal evidence.

### 4.2 Multi-gene biomarker panel for UC activity
- **Classification:** Biomarker.
- **Why prioritize:** Several differentially expressed genes encode secreted or easily measurable proteins, and non-invasive UC biomarkers remain clinically important.
- **Dataset evidence:** SLC6A14, LCN2, S100A8, MMP3, AQP8, and HMGCS2 show robust differential expression.
- **External evidence:** Fecal calprotectin (S100A8/A9) and NGAL/LCN2 are established or promising IBD biomarkers; MMP3 is elevated in IBD. SLC6A14 and AQP8 are less established and require validation.
- **Next step:** Independent cohort validation using qRT-PCR, NanoString, or ELISA; compare against endoscopic/histologic activity and fecal calprotectin; adjust for sex because SLC6A14 is X-linked.
- **Current conclusion:** Supported hypothesis for the panel; individual genes such as S100A8/LCN2 have stronger prior evidence.

### 4.3 Tissue-composition and epithelial-cell-loss check
- **Classification:** Confounding or composition check.
- **Why prioritize:** The “downregulation” of HMGCS2, AQP8, SLC transporters, CYP/UGT enzymes, and MEP1B may simply reflect loss of epithelial cells in inflamed UC mucosa.
- **Dataset evidence:** Bulk tissue cannot distinguish fewer epithelial cells from reduced expression per cell.
- **External evidence:** Histology of active UC shows crypt destruction, ulceration, and immune-cell infiltration; single-cell IBD studies support both composition changes and cell-intrinsic alterations.
- **Next step:** Single-cell/nuclei RNA-seq or flow-sorted EpCAM+ epithelial cells; perform deconvolution of the bulk data using epithelial, fibroblast, T-cell, B-cell, and myeloid references.
- **Current conclusion:** The metabolic epithelial-loss interpretation is exploratory until composition is accounted for.

### 4.4 Neutrophil–epithelial alarmin/chemokine amplification loop
- **Classification:** Interaction / network hypothesis.
- **Why prioritize:** CXCL1/2/3 and S100A8/LCN2 may form a self-amplifying loop between stressed epithelium and neutrophils.
- **Dataset evidence:** Simultaneous upregulation of neutrophil chemokines and alarmin/antimicrobial genes.
- **External evidence:** CXCL1/2/3 recruit neutrophils via CXCR2; S100A8/A9 can activate TLR4/RAGE; neutrophils release oxidants and proteases that further activate epithelium.
- **Next step:** Spatial transcriptomics or multiplex immunofluorescence to localize chemokines and alarmins; test CXCR2 blockade or S100A9 neutralization in experimental colitis.
- **Current conclusion:** Supported hypothesis, but the exact cellular source and direction of amplification need functional testing.

### 4.5 MMP3/ECM remodeling as a therapeutic target
- **Classification:** Therapeutic target.
- **Why prioritize:** MMP3 is strongly upregulated and connected to matrix degradation, ulceration, and fibrosis in chronic IBD.
- **Dataset evidence:** MMP3, TIMP1, TNC, PRRX1, PDPN, and TGM2 are coordinately upregulated.
- **External evidence:** MMP3 is elevated in IBD mucosa/serum; however, broad MMP inhibitors have failed in other diseases due to poor selectivity and toxicity. MMP3 may also be needed for epithelial restitution, so the net effect of inhibition is uncertain.
- **Next step:** Use conditional Mmp3 knockout or selective MMP3 inhibition in mouse colitis models; assess inflammation, fibrosis, and epithelial repair separately.
- **Current conclusion:** Exploratory hypothesis. The existence of MMP inhibitors does not by itself establish MMP3 as an effective target in UC.

---

## 5. Limitations and alternative explanations

1. **Bulk tissue composition and cell-proportion shifts.**  
   The mucosal sample contains epithelium, fibroblasts, endothelial cells, and infiltrating immune cells. Upregulated immune genes and downregulated epithelial genes could partly reflect cellular composition changes rather than cell-intrinsic expression changes. This can be addressed by single-cell RNA-seq, spatial transcriptomics, or computational deconvolution.

2. **Treatment exposure and disease severity.**  
   UC patients are often treated with 5-aminosalicylates, steroids, immunosuppressants, or biologics, all of which can affect immune and metabolic gene expression. No clinical metadata are provided, so treatment-related effects cannot be separated from disease biology. Ideally, validation cohorts should include untreated or well-phenotyped patients with recorded disease activity and extent.

3. **Probe and gene annotation ambiguity.**  
   Several entries are ambiguous or unusual: `CYP2B7P|CYP2B6`, `LOC100290146|IGHV4-31|IGHM|IGHG1|IGH`, `NAT8B|NAT8`, `C1QTNF3|AMACR`, `UBD|GABBR1`, and several unannotated `PROBE_*` items. Some downregulated genes, such as ABCB11, TAT, and LIPC, are classically liver-enriched and may represent cross-hybridization or unusual tissue expression. Targeted PCR or RNAscope is needed before assigning mechanism.

4. **Generic and overlapping inflammatory signals.**  
   Many of the observed changes—chemokines, alarmins, MMPs, and metabolic downregulation—are common to many forms of intestinal injury and infection. Without a Crohn’s disease, infectious colitis, or non-IBD inflammatory control group, these results cannot establish UC-specific biology.

5. **Association versus causation and lack of independent validation.**  
   The statistical support in the input is very strong, but differential expression alone does not establish causation. Functional perturbation is required. In addition, no independent cohort or pathway enrichment analysis was provided, so all biological-program interpretations should be treated as evidence-anchored hypotheses rather than confirmed findings.

---

In summary, the input transcriptome supports five major, partially overlapping biological programs in UC mucosa: antimicrobial/oxidative epithelial defense, neutrophilic NF-κB/IL-17-driven inflammation, loss of mature colonocyte metabolic/transport/detoxification functions, adaptive immune activation, and tissue remodeling/EMT-like change. The strongest candidate genes and modules for further work are DUOX2/DUOXA2, CXCL1/2/3, S100A8/LCN2, MMP3/TIMP1/TNC, HMGCS2/AQP8/ABCG2, IGH/CTLA4/DAPP1, IL1RN/SOCS3/IRAK3, SLC6A14, and PRRX1/PDPN/TGM2. The most urgent next step is not more differential-expression analysis, but rather cell-type-resolved, functionally perturbed validation of these candidate programs.
